1. Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz W, Wilmanns H, Kirchner H, Schoppe W, Petsch S, Bartels H, Pflüger KH, Teichmann J, Fuchs R, Kühn G, Oertel W, Mertelsmann R, Hecht T, Schalk KP, Worst P, Wilhelmy M, Gassmann W, Loos U, Hinterberger R, Theml H, Wagner T, Samandari S, Schäfgen W, Preiss J, Schmitz G, Mende W, Mödder B, Schick (1989a) Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacol 6:155–162
2. Diehl V, Pfreundschuh M, Löffler M, Rühl U, Hiller E, Gerhartz H, Kirchner H (1989b) Combined modality therapy for stages I–IIIA massive mediastinal Hodgkin's disease (MMHD): a randomized trial of two double cycles of COPP+ABVD pluse extended-field (EF) radiotherapy 40 Gy versus 20 Gy (Bulky Disease 40 Gy). Am Soc Clin Oncol 8:253
3. Löffler M, Pfreundschuh M, Hasenclever D, Hiller E, Gerhartz H, Wilmann W, Rohloff R, Rühl U, Kühn G, Fuchs R, Kirchner H, Teichmann J, Schoppe W, Petsch S, Wilhelmy W, Worst P, Pflüger KH, Hecht T, Bartels H, Gassmann W, Krüger G, Schmitz G, Oertel W, Diehl V (chairman) (1988) Prognostic risk factors in advanced Hodgkin's lymphoma. Blut 56:273–281
4. Pfreundschuh M, Diehl V (1989) Therapie rezidivierender Hodgkin Lymphome. II. Der Stellenwert der Knochenmarktransplantation. Dtsch Med Wochenschr 114:916–921
5. Pfreundschuh M, Schoppe W, Fuchs R, Pflüger KH, Löffler M, Diehl V (1987) Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkins' lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treat Rep 71:1203–1207